论文部分内容阅读
目的观察国产抗肿瘤血管生成剂重组人血管内皮抑制素(恩度)与联合TCF方案治疗晚期胃癌的临床效果和安全性及生活质量评分。方法 2009年1月～2010年10月,64例晚期胃癌患者随机分为2组,各32例,治疗组应用Taxol+DDP+5-Fu方案化疗同时联合恩度15 mg/d,加入生理盐水500 ml内静滴,连用14 d为1疗程,对照组单用Tax-ol+DDP+5-Fu方案21 d为1个周期,连用2个周期后评价疗效,生活质量改变,不良反应,并记录中位疾病进展时间。结果治疗组和对照组的有效率分别为(62.5%)和(34.38%)(χ2=5.067,P﹤0.05)。治疗组生活质量明显提高(P﹤0.05)。中位疾病进展时间分别为7.2个月及4.1个月(P﹤0.05)。结论恩度联合TCF方案治疗晚期胃癌,能显著提高疗效,提高生活质量,延长中位疾病进展时间,且不增加治疗后不良反应的发生率,值得进一步积累病例和积极开展多中心临床协作研究。
Objective To observe the clinical efficacy, safety and quality of life of domestic anti-tumor angiogenesis agent recombinant human endostatin (Endostar) and combined TCF regimen in the treatment of advanced gastric cancer. Methods From January 2009 to October 2010, 64 patients with advanced gastric cancer were randomly divided into 2 groups (32 in each). The patients in the treatment group were treated with Taxol + DDP + 5-Fu chemotherapy combined with Endostar 15 mg / d, 500ml of intravenous infusion, once every 14 days for a course of treatment, the control group with Tax-ol + DDP + 5-Fu program 21 d for a cycle, even after 2 cycles evaluation of efficacy, quality of life changes, adverse reactions, and Record the median disease progression time. Results The effective rates of the treatment group and the control group were 62.5% and 34.38%, respectively (χ2 = 5.067, P <0.05). The quality of life in the treatment group was significantly improved (P <0.05). The median time to progression was 7.2 months and 4.1 months, respectively (P <0.05). Conclusions The combination of Endostar and TCF regimen in the treatment of advanced gastric cancer can significantly improve the curative effect, improve the quality of life, prolong the median time to progression, and not increase the incidence of adverse reactions after treatment. It is worth further accumulating cases and conducting multicenter clinical collaborative research.